Publication number: 20260191835
Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.
Type:
Application
Filed:
November 29, 2023
Publication date:
July 9, 2026
Inventors:
Nikki DASKALAKIS,, Diane Christina GUTTKE, Min Chul KWON, Lucille Angela FERRANTE, Kathryn Elizabeth PACKMAN, Eva Christine PIETSCH, Ulrike PHILIPPAR, Sumia ALI-AHMED, Wei CAI, Johannes Wilhelmus J. THURING, Fabian HULPIA, Xuedong DAI, Ming LI, Xiangjun DENG, Chao LIANG, Alicia Tee Fuay NG, Zhen SUN, Zhigao ZHANG, Samuël Dominique DEMIN, Natalia Nikolaevna DYUBANKOVA, Matthieu Dominique JOUFFROY, Susan LEPRI, Nicolas Freddy J DARVILLE, Vineet PANDE, Wim Bert Griet SCHEPENS, James Patrick EDWARDS, Olivier Alexis Georges QUEROLLE
Publication number: 20250302840
Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.
Type:
Application
Filed:
May 9, 2022
Publication date:
October 2, 2025
Inventors:
Nikki Daskalakis, Christian Diane Guttke, Min Chul Kwon, Lucille Angela Ferrante, Kathryn Elizabeth Packman, Eva Christine Pietsch, Ulrike Philippar, Tinne Ann J. Verhulst, Balpreet Bhogal, Yu Sun, Wei Cai, Xuedong Dai, Olivier Alexis Georges Querolle, Johannes Wilhelmus J. Thuring, Yingtao Liu, Lianzhu Liu, Yanping Xu, Liqiang Fu, Ming Li, Lichao Fang, Xiangjun Deng, Alicia Tee Fuay NG, Nicolas Freddy J. Darville, Vineet Pande
Publication number: 20240261292
Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.
Type:
Application
Filed:
May 9, 2022
Publication date:
August 8, 2024
Inventors:
Nikki Daskalakis, Christina Diane Guttke, Min Chul Kwon, Lucille Angela Ferrante, Kathryn Elizabeth Packman, Eva Christine Pietsch, Ulrike Philippar, Tinne Ann J. Verhulst, Sumia Ali-Ahmed, Balpreet Bhogal, Yu Sun, Wei Cai, Xuedong Dai, Olivier Alexis Georges Querolle, Johannes Wilhelmus J. Thuring, Yingtao Liu, Lianzhu Liu, Yanping Xu, Liqiang Fu, Ming Li, Lichao Fang, Xiangjun Deng, Alicia Tee Fuay Ng, Nicolas Freddy J. Darville, Vineet Pande
© 2026 Justia
